Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ: HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.
Is now the time to buy Halozyme Therapeutics? Find out by accessing our full research report, it’s free.
Halozyme Therapeutics (HALO) Q2 CY2026 Highlights:
- Revenue: $481 million vs analyst estimates of $404.3 million (47.7% year-on-year growth, 19% beat)
- Adjusted EPS: $2.28 vs analyst estimates of $1.82 (25.5% beat)
- Adjusted EBITDA: $328.8 million vs analyst estimates of $267.2 million (68.4% margin, 23.1% beat)
- The company lifted its revenue guidance for the full year to $1.87 billion at the midpoint from $1.76 billion, a 6.4% increase
- Management raised its full-year Adjusted EPS guidance to $8.83 at the midpoint, a 10.3% increase
- EBITDA guidance for the full year is $1.25 billion at the midpoint, above analyst estimates of $1.16 billion
- Operating Margin: 59.8%, down from 62.2% in the same quarter last year
- Market Capitalization: $9.91 billion
"We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.
Company Overview
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ: HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, Halozyme Therapeutics’s 32.2% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Halozyme Therapeutics’s annualized revenue growth of 38% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. 
This quarter, Halozyme Therapeutics reported magnificent year-on-year revenue growth of 47.7%, and its $481 million of revenue beat Wall Street’s estimates by 19%.
Looking ahead, sell-side analysts expect revenue to grow 15.5% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is commendable and implies the market sees success for its products and services.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Halozyme Therapeutics has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 55.7%.
Looking at the trend in its profitability, Halozyme Therapeutics’s adjusted operating margin decreased by 9.2 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 11.7 percentage points on a two-year basis. We’re disappointed in these results because they show its expenses were rising and it couldn’t pass those costs onto its customers.
This quarter, Halozyme Therapeutics generated an adjusted operating margin profit margin of 63.5%, down 7.7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Halozyme Therapeutics’s EPS grew at an astounding 24.7% compounded annual growth rate over the last five years. However, this performance was lower than its 32.2% annualized revenue growth, telling us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
Diving into Halozyme Therapeutics’s quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Halozyme Therapeutics’s adjusted operating margin declined by 9.2 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Halozyme Therapeutics reported adjusted EPS of $2.28, up from $1.54 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Halozyme Therapeutics’s full-year EPS to grow 76.1% from $5.36 to $9.44.
Key Takeaways from Halozyme Therapeutics’s Q2 Results
It was good to see Halozyme Therapeutics beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a solid print. The stock traded up 4.4% to $89.69 immediately following the results.
Halozyme Therapeutics may have had a good quarter, but does that mean you should invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
